Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Clinical trial NCT03277482 · TERMINATED

Trial details

NCT number: NCT03277482
Sponsor: Dana-Farber Cancer Institute
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Gynecological Cancer Metastatic Cervical Cancer Metastatic Ovarian Cancer Metastatic Vaginal Cancer Metastatic Vulvar Cancer Metastatic Endometrial Cancer Recurrent Cervical Carcinoma Recurrent Ovarian Carcinoma Recurrent Vaginal Cancer Recurrent Vulvar Cancer Recurrent Endometrial Cancer

Start date: 2018-06-01
Primary completion: 2022-07-15
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.